Literature DB >> 26378642

Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.

Michele Vacca1, Michael Allison2, Julian L Griffin1, Antonio Vidal-Puig3.   

Abstract

The term nonalcoholic fatty liver disease (NAFLD) covers a pathologic spectrum from lipid accumulation alone (simple steatosis) to steatosis with associated inflammation and fibrosis (nonalcoholic steatohepatitis [NASH]). Nonalcoholic steatohepatitis can progress to cirrhosis and potentially to hepatocellular carcinoma. Although a genetic predisposition has been highlighted, NAFLD is strongly associated with an unhealthy lifestyle and hypercaloric diet in the context of obesity and metabolic disease. The dysregulation of specific pathways (insulin signaling, mitochondrial function, fatty acid, and lipoprotein metabolism) have been linked to steatosis, but elucidating the molecular events determining evolution of the disease still requires further research before it can be translated into specific personalized interventional strategies. In this review, the authors focus on the early events of the pathophysiology of NASH, dissecting the metabolic and nutritional pathways involving fatty acids and glucose sensors that can modulate lipid accumulation in the liver, but also condition the progression to cirrhosis and hepatocellular carcinoma. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26378642     DOI: 10.1055/s-0035-1562945

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  14 in total

1.  Human GDPD3 overexpression promotes liver steatosis by increasing lysophosphatidic acid production and fatty acid uptake.

Authors:  Chia-Chi C Key; Andrew C Bishop; Xianfeng Wang; Qingxia Zhao; Guan-Yuan Chen; Matthew A Quinn; Xuewei Zhu; Qibin Zhang; John S Parks
Journal:  J Lipid Res       Date:  2020-05-19       Impact factor: 5.922

Review 2.  Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

Authors:  Paul D Berk; Elizabeth C Verna
Journal:  Clin Liver Dis       Date:  2016-02-18       Impact factor: 6.126

3.  Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial.

Authors:  Christopher Papandreou; Mònica Bullò; Francisco José Tinahones; Miguel Ángel Martínez-González; Dolores Corella; Georgios A Fragkiadakis; José López-Miranda; Ramon Estruch; Montserrat Fitó; Jordi Salas-Salvadó
Journal:  Nutr Metab (Lond)       Date:  2017-09-02       Impact factor: 4.169

4.  Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.

Authors:  Zoe Hall; Nicholas J Bond; Tom Ashmore; Francis Sanders; Zsuzsanna Ament; Xinzhu Wang; Andrew J Murray; Elena Bellafante; Sam Virtue; Antonio Vidal-Puig; Michael Allison; Susan E Davies; Albert Koulman; Michele Vacca; Julian L Griffin
Journal:  Hepatology       Date:  2017-02-06       Impact factor: 17.425

Review 5.  Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer.

Authors:  Can Cheng; Songming Zhuo; Bo Zhang; Xu Zhao; Ying Liu; Chaoliang Liao; Jing Quan; Zhenzhen Li; Ann M Bode; Ya Cao; Xiangjian Luo
Journal:  Int J Biol Sci       Date:  2019-06-04       Impact factor: 6.580

Review 6.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

7.  Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease.

Authors:  Jean-Christophe Simard; Jean-François Thibodeau; Martin Leduc; Mikael Tremblay; Alexandre Laverdure; François Sarra-Bournet; William Gagnon; Jugurtha Ouboudinar; Liette Gervais; Alexandra Felton; Sylvie Letourneau; Lilianne Geerts; Marie-Pier Cloutier; Kathy Hince; Ramon Corpuz; Alexandra Blais; Vanessa Marques Quintela; Jean-Simon Duceppe; Shaun D Abbott; Amélie Blais; Boulos Zacharie; Pierre Laurin; Steven R Laplante; Christopher R J Kennedy; Richard L Hébert; François A Leblond; Brigitte Grouix; Lyne Gagnon
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 8.  Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma.

Authors:  Divya Jain; Yogesh Murti; Wasi Ullah Khan; Rajib Hossain; Mohammad Nabil Hossain; Krishn Kumar Agrawal; Rana Azeem Ashraf; Muhammad Torequl Islam; Pracheta Janmeda; Yasaman Taheri; Mohammed M Alshehri; Sevgi Durna Daştan; Balakyz Yeskaliyeva; Aliya Kipchakbayeva; Javad Sharifi-Rad; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-10-31       Impact factor: 6.543

9.  Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis.

Authors:  Michele Vacca; Jack Leslie; Samuel Virtue; Brian Y H Lam; Olivier Govaere; Dina Tiniakos; Sophie Snow; Susan Davies; Kasparas Petkevicius; Zhen Tong; Vivian Peirce; Mette Juul Nielsen; Zsuzsanna Ament; Wei Li; Tomasz Kostrzewski; Diana Julie Leeming; Vlad Ratziu; Michael E D Allison; Quentin M Anstee; Julian L Griffin; Fiona Oakley; Antonio Vidal-Puig
Journal:  Nat Metab       Date:  2020-06-08

Review 10.  Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.

Authors:  Maria Grazia Clemente; Claudia Mandato; Marco Poeta; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.